Nephrolithiasis Clinical Trial
— FAGOTRICIAOfficial title:
Experimental Study of the Administration of a Food Supplement Containing Hydroxycitric Acid Versus Placebo in Patients With Oxalate and Calcium Phosphate Lithiasis in Whom Extracorporeal Shock Wave Lithotripsy is Indicated.
Verified date | February 2023 |
Source | Arafarma Group, S.A. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The extracorporeal shock wave lithotripsy (ESWL) is the treatment of choice for most stones in any of their locations. It is about breaking the stone without surgically intervening on the patient and getting him to expel the fragments himself. It is thought that additional treatments to the ESWL could improve the success rate of ESWL for less favorable stones. The components of our authorized food supplement have shown an inhibitory effect in vitro on the growth of calcium oxalate monohydrate crystals, even in hightly supersaturared solutions. Also these components show an inhibitory effect on the growth of calcium phosphate crystals. To sum up, it reduces the formation, inhibits the growth and promotes the dissolution of calcium oxalate and calcium phosphate kidney stones. This is the reason why this experimental study aims to modify the size limit of the stones in the ESWL with adjuvant food supplement.
Status | Completed |
Enrollment | 81 |
Est. completion date | October 5, 2022 |
Est. primary completion date | September 16, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Renal lithiasis with high radiological and clinical suspicion of calcium oxalate or calcium phosphate, size of the largest diameter between 1.5x1cm and 2x1cm, which will be treated by ESWL, being symptomatic with little probability of spontaneous expulsion. - Signed informed consent to participate in the clinical study. Exclusion Criteria: - Lithiasis of more than 20 mm and less than 15 mm for the largest diameter. - Taking medications with influence on urinary lithogenesis (citrate, bicarbonate, thiazides, bisphosphonates, magnesium, calcium, vitamin B6, vitamin D, vitamin A, xanthine-oxidase inhibitors, uricosurics, probiotics, urease inhibitors, cystine binders, topiramate , antiretrovirals). - Taking medications that influence urine pH (citrate, bicarbonate, carbonic anhydrase inhibitors, L-methionine, vitamin C, ammonium chloride). - Taking selective serotonin reuptake inhibitor antidepressant medications. - Taking anticoagulants and antiaggregants. - ESWL contraindications: urine infection, active or recurrent; hemorrhagic diathesis; pregnant or lactating patients; others (extreme obesity, arterial aneurysm near the location of the stone, etc.). |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Universitario Clínico San Cecilio | Granada | |
Spain | Hospital Universitario Regional de Málaga | Málaga | |
Spain | Hospital Universitario Virgen de Valme | Sevilla |
Lead Sponsor | Collaborator |
---|---|
Arafarma Group, S.A. |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Efficacy of extracorporeal shock wave lithotripsy (ESWL) measured as reduction of the size (area) of lithiasis between both treatment groups. | To assess the level of fragmentation of lithiasis which is treated with ESWL by measuring the % of reduction of the size (area) of lithiasis through imaging tests. | 10 weeks after baseline visit | |
Primary | Efficacy of extracorporeal shock wave lithotripsy (ESWL) measured as number of generated fragments between both treatment groups. | To assess the level of fragmentation of lithiasis which is treated with ESWL by measuring the number of generated fragments through imaging tests. | 10 weeks after baseline visit | |
Primary | Efficacy of extracorporeal shock wave lithotripsy (ESWL) measured as the hardness of lithiasis between both treatment groups. | To assess the level of fragmentation of lithiasis which is treated with ESWL by measuring the hardness of lithiasis through imaging tests. | 10 weeks after baseline visit | |
Secondary | Rate of morbidities related to the ESWL between both treatment groups. | All episodes of morbidities related to the ESWL will be recorded, whether considered relevant. | 2 weeks and 6 weeks after ESWL |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04746378 -
PRedictive Accuracy of Initial Stone Burden Evaluation.
|
||
Recruiting |
NCT05100017 -
Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure
|
N/A | |
Recruiting |
NCT03692715 -
Antibiotic Prophylaxis Before Shock Wave Lithotripsy
|
Phase 4 | |
Completed |
NCT02547805 -
Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days
|
Phase 2 | |
Completed |
NCT02289755 -
Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria
|
Phase 2 | |
Completed |
NCT01650935 -
Comparison of DASH With Oxalate Restricted Diet on Urine in Recurrent Stone Formers With Hyperoxaluria
|
N/A | |
Completed |
NCT01690039 -
Influence of Polymorphisms in the ATP6V1 Gene of the V-ATPase on the Development of Incomplete Distal Renal Tubular Acidosis
|
||
Completed |
NCT01295879 -
Vitamin D Repletion in Stone Formers With Hypercalciuria
|
Phase 4 | |
Recruiting |
NCT05014178 -
Kidney Sodium Functional Imaging
|
||
Not yet recruiting |
NCT06199102 -
The High Initial Dose of Monitored Vitamin D Supplementation in Preterm Infants.
|
N/A | |
Recruiting |
NCT04367155 -
Efficacy of Tranexamic Acid on Blood Loss During Percutaneous Nephrolithotomy.
|
N/A | |
Recruiting |
NCT04374188 -
Efficacy of Ciprofloxacin Therapy in Avoidance of Sepsis in Patient Undergoing Percutanous Nephrolithotomy
|
N/A | |
Recruiting |
NCT05701098 -
SOUND Pivotal Trial - (Sonomotion stOne comminUtion resoNance ultrasounD)
|
N/A | |
Recruiting |
NCT04389853 -
Mini-PNCL vs fURS in Management of Nephrolithiasis
|
N/A | |
Completed |
NCT03348228 -
Effect of Hydroxycitrate on Urine Chemistry
|
N/A | |
Completed |
NCT05350423 -
Trial Assessing Renal Damage During Ureteroscopy
|
N/A | |
Completed |
NCT03454139 -
Subcostal TAP Block For Percutaneous Nephrolithotomy
|
N/A | |
Recruiting |
NCT02279927 -
Prospective Comparison Between Different Laser Settings for Ureteral \ Kidney Stones Treatment During Ureteroscopy
|
N/A | |
Completed |
NCT02276924 -
Diagnostic Relevance of Laser Confocal Microscopy for the Screening of Upper Urinary Tract Tumors
|
N/A | |
Completed |
NCT00159393 -
Percutaneous Nephrolithotomy: A Registry and Database
|